This current study will test the long-term safety and tolerability of Vilazodone and will enroll patients at 40 sites in the US. A second pivotal trial will continue the evaluation of genetic biomarkers of response to Vilazodone that were identified in the first pivotal trial announced by the company in September 2007.
Drew Fromkin, president and CEO of Clinical Data, said: “By launching this trial, Clinical Data continues to demonstrate its ability to independently move a promising compound through the development process. We are encouraged by the results of our recently completed pivotal study of Vilazodone, which suggests that it has important benefits as a stand-alone compound for patients with depression. With the addition of a genetic test for response to Vilazodone, we can help clinicians more quickly and confidently identify patients who are likely to respond, leading to improvements in patient care and outcomes.”